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Abstract: 
 
Purpose: The tumor growth kinetics of the human LoVo colorectal xenograft 
model was assessed in response to vandetanib, an orally available receptor 
tyrosine kinase inhibitor, radiotherapy (RT) or irinotecan (CPT-11), as single 
therapies and in combination.  
Methods and Materials:  LoVo cells were injected subcutaneously into the 
right hind limb (5 x 106 cells in 100 µl PBS) of athymic NCR NUM mice and 
tumors were grown to a volume of 200-300 mm3 before treatment.  
Vandetanib was administered at 50 mg/kg daily p.o. for 14 days starting on 
day 1.  RT was given as three fractions (3 x 3 Gy) on days 1, 2 and 3.  CPT-
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11 was given at 15 mg/kg i.p. on days 1 and 3.  Tumor volumes were 
measured on a daily basis and calculated by measuring tumor diameters with 
digital calipers in two orthogonal dimensions. 
Results: All three single treatments (vandetanib, CPT-11 and radiation) 
significantly slowed LoVo colorectal tumor growth. Vandetanib significantly 
increased the antitumor effects of CPT-11 and radiation, when given in 
combination with either of these treatments. These treatment combinations 
resulted in a slow tumor growth rate during the two weeks of vandetanib 
administration. The triple combination of vandetanib, CPT-11, and radiation 
produced the most marked improvement in response as observed by 
measurable shrinkage of tumors during the first week of treatment. 
Conclusions: The tumor growth delay kinetics observed in this study of the 
LoVo colorectal model suggest concurrent and sustained post-sequencing of 
vandetanib with cytotoxic therapy may be beneficial in tumors of this type.  
 
Key Words: 
Vandetanib, radiotherapy, CPT-11, LoVo colorectal cancer, angiogenesis 
inhibitor 
 
 
 
Introduction  
Colorectal cancer (CRC) remains one of the leading causes of mortality 
worldwide. In recent years, the most widely used chemotherapy for metastatic 
CRC, fluoropyrimidine (5-fluorouracil (5-FU)) in combination with folinic acid 
(FA), has been combined with newer, highly active cytotoxic agents. Among 
these agents is the DNA topoisomerase I inhibitor, irinotecan (CPT-11) 1, a 
potent DNA-targeting drug used in patients with CRC that is refractory to 
treatment with fluorouracil and leucovorin. This cytotoxic agent is, in turn, 
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currently being combined with new molecular therapies targeting the tumor 
vasculature and key signaling pathways controlling tumor cell proliferation, 
angiogenesis and survival in CRC.  In this regard, the epidermal growth factor 
receptor (EGFR) plays an important role in CRC tumor growth and 
progression 2, and cetuximab, a monoclonal antibody (MAB) specific for 
EGFR, has been approved for use in combination with CPT-11 in patients 
with EGFR-expressing CRC refractory to CPT-11-based chemotherapy 3.  In 
addition, bevacizumab, a MAB specific for vascular endothelial growth factor 
(VEGF-A), a key player in tumor angiogenesis in CRC as well as other solid 
tumors, has been approved for the treatment of metastatic CRC in 
combination with intravenous 5-FU-based chemotherapies 4. Despite recent 
improvements in treatment for CRC, a need still remains to improve the 
performance of existing treatments and to establish the optimum scheduling 
and dosing of combined therapies.  
 
Vandetanib (ZACTIMATM) is an oral receptor tyrosine kinase inhibitor that, in 
recombinant enzyme assays, demonstrates potent activity against VEGFR-2 
tyrosine kinase (IC50 = 40 nmol/L) with additional activity against EGFR (IC50 
= 500 nmol/L) and RET (IC50 = 130 nM) tyrosine kinases 5-8.  Vandetanib 
currently has orphan-drug status in the USA and Europe for medullary thyroid 
cancer (MTC) (in which RET activity is important) and is in Phase III 
development in non-small-cell lung cancer and MTC. Phase II studies are 
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ongoing to investigate its efficacy in other tumor types, thyroid cancer, 
hepatocellular carcinoma and glioblastoma. 
 
Vandetanib has been shown to enhance the efficacy of radiotherapy in 
subcutaneous (s.c.) and orthotopic tumor xenograft models 9-13. The 
combination of vandetanib, radiation and current chemotherapeutic agents 
used in CRC treatment has not been studied to date. Preclinical 
demonstration of efficacy of a combination protocol with novel agents plus 
radiation is usually considered crucial prior to clinical evaluation. The purpose 
of the present study was to examine the effect of vandetanib on the radiation 
response of a colorectal tumor model when administered in combination with 
CPT-11. It was hypothesized that simultaneous inhibition of VEGFR and 
EGFR by vandetanib in combination with the cytotoxic agent CPT-11 would 
interact to enhance radiation response and tumor control in the human LoVo 
colorectal tumor cell model. The LoVo colorectal model expresses activated 
EGFR 14, 15 and is highly vascularized, and therefore is an appropriate model 
to test the hypothesis. 
 
Materials and Methods 
Animal and Tumor Model: LoVo cell suspensions (5 x 106 cells in 100 µl 
phosphate buffered saline) were implanted s.c. into the right hind limbs of 6-8 
week-old athymic NCR NUM mice (Taconic Farms, Hudson, NY). A s.c. 
xenograft model was chosen to facilitate radiation dosing and ease of tumor 
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measurements. Tumors were allowed to grow for approximately 25 days, until 
reaching an approximate volume of 200-300 mm3 at the start of treatment 
(day 1). All animals were randomized among treatment groups. 
 
Drug Treatment: Vandetanib (AstraZeneca, Macclesfield, UK) was 
administered by oral gavage (p.o.) at 50 mg/kg daily for 14 days, starting on 
day 1. Vandetanib dosing in this study was based on previous 
pharmacokinetic studies in mouse models predicting relevance of this dosing 
to clinical drug exposure in human patients 16. CPT-11 was given at 15 mg/kg 
intraperitoneally (i.p.) on days 1 and 3.  
 
Radiation Treatment: Irradiation was performed on anesthetized mice using 
X-rays generated by a PanTak, 310 kVe x-ray machine, 0.25 mm Cu + 1 mm 
Al added filtration, at 125 cGy per min. Dosimetry was performed by an in-
the-beam ionization chamber calibrated against a primary standard. 
Corrections were made daily for humidity, temperature and barometric 
pressure. Mice were anesthetized with a combination of ketamine and 
acepromazine at a concentration of 37.5 mg/kg and 0.2 mg/kg, respectively, 
to provide 25-30 minutes of sedation. Each mouse was confined in a lead 
casing with its tumor-bearing leg extended through an opening on the side to 
allow the tumor to be irradiated locally. Radiation was administered as three 
daily fractions of 3 Gy each on days 1, 2, and 3. On days when radiation was 
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administered with vandetanib and/or CPT-1, vandetanib and CPT-11 were 
given approximately 2 hours before radiation, with vandetanib preceding 
CPT-11 administration. 
 
Tumor Measurement: Tumors were synchronized to be approximately 250 
mm3 at the start of treatment (day 1) and were measured four to five times per 
week, for up to six weeks of follow-up, or until they reached 2,000 mm3. 
Tumor size was determined by direct measurement with calipers and 
calculated by the formula: (smallest diameter2 x widest diameter)/2. Tumors 
were not allowed to grow beyond 2,000 mm3 in accordance with Institutional 
Animal Care and Use Committee regulations. 
 
In-vivo Tumor Necrosis: Tumors were collected from animals on day 14 
following start of treatment for fixation and staining with H&E. The area of 
necrosis was evaluated by image analysis and expressed as the percentage 
of the total tumor area. 
 
Statistical Analysis Tumor growth was analyzed via mixed-effects 
regression, as previously described The method was used because it does 
not depend on an arbitrary endpoint target tumor size, but utilizes the 
repeated tumor size measurements obtained over the entire study period, 
while appropriately handling unbalanced data (i.e., different number of 
measurements for different animals) and the correlation of each animal’s 
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measurements over time. Mixed-effects regression yields generalizable 
parameters of interest (e.g., average daily tumor growth rate and tumor 
doubling time), and can investigate treatment interactions and non-linear 
patterns of tumor growth. The base-10 logarithm of tumor volume was 
modeled as a function of time and treatment. Linear or quadratic growth 
curves over time were fitted to the log-transformed data, depending on growth 
patterns in each treatment groupAll statistical analyses were conducted in 
SAS 9.2 (SAS Institute Inc., Cary, NC, 1999-2001). 
Results 
The experiment involved three different treatments (vandetanib, CPT-11, and 
radiotherapy), as described above and summarized in Figure 1. Data were 
collected from a total of 104 animals in eight experimental groups (11-16 
animals per group) and are summarized in Figure 2. Starting tumor sizes 
were comparable across groups, with geometric means ranging from 230 to 
257 mm3 (p = 0.771). All treatments were well tolerated in the animals with no 
observable loss of body weight. 
 
 
The three single-treatment groups (CPT-11, radiation, or vandetanib), as well 
as the combination of CPT-11 with radiation (Figure 2) were fitted to log 
transformed curves, while the three remaining groups that received 
combination treatments involving vandetanib showed a significantly non-linear 
tumor growth and were fitted to quadratic curves.  
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Figure 3 shows the measured geometric mean tumor size graphically over 
time. Table 1 shows the corresponding calculated tumor growth parameters 
(daily tumor growth rate and tumor doubling time). Table 2 shows p-values for 
group comparisons at 7, 14, and 21 days after start of treatment. 
 
The control group had an estimated average daily tumor growth rate of 9.9%, 
corresponding to an average tumor doubling time of about 7 days (Table 1). 
All three single treatments resulted in a significant inhibition of tumor growth, 
compared with the control group (average daily tumor growth rates: CPT-11: 
7.1%, p = 0.015; radiation: 5.6%, p = 0.001; vandetanib: 5.0%, p = 0.001) 
Vandetanib inhibited tumor growth significantly more than CPT-11 (p = 0.043) 
but not radiation (p = 0.514); radiation and CPT-11 were not significantly 
different (p = 0.139). The combination of CPT-11 with radiation produced a 
daily tumor growth rate of 5.1%, which was significantly lower than CPT-11 
alone (p = 0.015) but comparable to radiation alone (p = 0.560). There was no 
significant (additive) interaction between CPT-11 and radiation (p = 0.105).  
 
The remaining three groups which received treatment combinations involving 
vandetanib (with either CPT-11 or radiation, or with both CPT-11 and 
radiation), showed significant treatment interactions (p = 0.001 for the 
interaction between vandetanib and CPT-11 and between vandetanib and 
radiation) and non-linear tumor growth patterns. Compared to single-
treatment groups, growth was significantly delayed (and, in the triple-
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treatment combination, tumor volume actually decreased) early on, but 
progressively accelerated later, although it never exceeded that of the 
untreated controls (Figure 3). Because of the non-linearity of tumor growth in 
these groups, tumor growth parameters are not constant over time and 
comparisons depend on the timepoint referenced. Table 2 shows p-values for 
days 7, 14, and 21. 
 
During the first week of treatment, animals receiving the combination of 
vandetanib with CPT-11 had average daily tumor growth rate of less than 
3.5%, significantly lower than CPT-11 alone and marginally so compared to 
vandetanib alone (p = 0.001 and 0.058, respectively, after 7 days). By the end 
of the two-week vandetanib treatment, the tumor growth rate in the 
combination group (4.6%) was still significantly lower than for CPT-11 alone 
(p = 0.015) but comparable to that for vandetanib alone (p = 0.682). By the 
third and fourth weeks, tumor growth had reached levels similar to those seen 
in the single-treatment groups (Figure 3, Table 1).  
 
The combination of vandetanib with radiation resulted in a similar pattern of 
non-linear tumor growth inhibition. After the first 7 days, the average daily 
tumor growth rate of 2.1% was significantly lower than for either radiation 
alone or vandetanib alone (p = 0.005 and 0.019, respectively). After 14 days, 
the tumor growth rate in the combination group had accelerated to 3.4% and 
was only marginally lower than for radiation alone and comparable to that for 
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vandetanib alone (p = 0.080 and 0.212, respectively). By the third and fourth 
weeks, tumor growth had become similar to that seen in the single-treatment 
groups (Figure 3, Table 1).  
 
Despite delaying tumor growth in the initial weeks, the treatment 
combinations induced only modest levels of tumor necrosis (10-20%), with no 
significant differences between treatment groups (Figure 4).  
 
The pattern of tumor growth in the group that received the triple-treatment 
combination reflected both the interaction between vandetanib and CPT-11 
and that between vandetanib and radiation (as mentioned previously). Thus, 
during the first week, instead of the delayed tumor growth seen in the two-
treatment combinations, tumor volume in the triple-treatment combination 
actually decreased (p = 0.001 versus vandetanib plus CPT-11, and 0.052 
versus vandetanib plus radiation). After that time, similar to the two-treatment 
combinations that involved vandetanib, tumor growth started accelerating. By 
the end of the third week, tumor growth in the triple-treatment combination 
group was similar to that in the two-treatment combination groups involving 
vandetanib, and by the fourth week, it was similar to that in the single-
treatment groups.  
 
Discussion 
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Relatively little is known about the antitumor effects of combining cytotoxic 
drugs, radiotherapy, and novel targeted therapies that specifically interfere 
with signaling pathways controlling cancer proliferation, angiogenesis and 
survival. In the present study, vandetanib, a potent inhibitor of both VEGFR 
and EGFR signaling, was combined with CPT-11 and/or radiation, to 
determine if greater anti-colorectal tumor activity can be obtained. 
 
This study demonstrated that all three single treatments (vandetanib, CPT-11 
and radiation) significantly slowed LoVo colorectal tumor growth. Previous 
studies with single-agent vandetanib demonstrated that chronic oral 
administration reduced tumor vascularity and tumor growth in a variety of 
xenograft models, including CRC 7, 17.  In the clinic, the safety and tolerability 
of vandetanib has been demonstrated in patients with advanced colorectal 
cancer as well as other solid tumors18. Vandetanib induced manageable 
normal tissue toxicities related to inhibition of EGFR and VEGFR signaling 
such as diarrhea, rash and hypertension19, 20. The effect of combining 
radiation and vandetanib on normal tissue is currently unknown, however it 
has been shown in both preclinical and clinical trials that use of VEGF 
inhibitors with radiation may result in higher rates of normal tissue toxicity 
such as  induction of  thrombosis, hemorrhage and bowel toxicities 21-23. In 
contrast, it was postulated that combination of radiotherapy with inhibitors of 
angiogenesis may actually decrease these risks because radiotherapy has 
been used to prevent hemorrhage 24. Overall the investigation of agents such 
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as vandetanib in combination with radiation in normal tissue are lacking, and 
thus will be a major focus in the future.   
 
 
As previously discussed, single agent vandetanib has dual tyrosine kinase 
inhibitory  activity against VEGFR-2 and EGFR which allows it to target two 
key pathways responsible for tumor growth, i.e., tumor angiogenic signaling 
and tumor cell proliferation. It has been speculated that dual suppression may 
be critical for sustained suppression of tumor growth, especially since the 
EGFR and VEGFR pathways are linked and exhibit cross-talk 25.  In addition, 
vandetanib can also enhance the antiproliferative activity of selective  EGFR 
inhibitors such as cetuximab, thereby potentiating suppression of EGFR 
signaling17. 
 
The present study confirmed that vandetanib, chronically administered over 
two weeks, slowed tumor growth in a colorectal tumor model, and, under the 
dosing conditions of this study, slowed tumor growth to a greater extent than 
CPT-11 alone and to a similar level to radiation alone. Moreover, vandetanib 
significantly increased the antitumor effects of CPT-11 and radiation, when 
given in combination with either of these treatments. In particular, these 
treatment combinations resulted in a slow tumor growth rate during the two 
weeks of vandetanib administration. These results confirm an earlier study by 
Troiani et al. 26, in which vandetanib (25 mg/kg/day) administered in 
combination with CPT-11 exhibited high antitumor activity in HT29-tumor-
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bearing nude mice. Troiani et al. showed a correlation between this dosing 
schedule and enhanced EGFR and VEGFR signal inhibition.   
In the present study, the triple combination of vandetanib, CPT-11, and 
radiation produced the most marked improvement in response in the LoVo-
tumor-bearing mice. The triple treatment produced a measurable shrinkage of 
tumors during the first week of treatment. The combination of vandetanib, 
chemotherapy (gemcitabine), and radiation has also been previously shown 
to significantly inhibit tumor progression in a pancreatic tumor model 27. 
Importantly, the present study also investigated the kinetics of tumor growth, 
both during and after a course of treatment. It was demonstrated that the 
addition of vandetanib significantly enhanced the initial antitumor effect of 
chemo-radiation. However, when vandetanib treatment ended, tumor growth 
returned to near control (untreated) levels. Therefore, these data support the 
rationale of adding an anti-vascular agent to cytotoxic therapies and provide 
valuable information for the design of therapeutic protocols.   
 
The precise mechanisms leading to initial tumor regression with the combined 
therapies in this study are not known. Analysis of interactions between 
cytotoxic agents and vandetanib is complex, given that both the tumor cells 
and the tumor microenvironment are affected. In this connection, radiation 
can kill not only tumor cells but also endothelial cells of the tumor vasculature, 
thereby affecting the radiosensitivity of the tumor 28, 29. In addition, cytotoxic 
agents have mechanisms of cell killing that are different from the targeted 
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agent. Both radiation and CPT-11 kill cells through DNA damage. Both 
chemotherapy and radiation can also alter cellular signaling pathways by 
inducing EGFR phosphorylation and through the growth factor signaling 
pathway, contribute to tumor cell proliferation and survival 30-32. Preclinical 
studies have also shown that cytotoxic therapy alone, such as radiation, can 
result in intensification of angiogenic processes 33. After cytotoxic treatment, 
up-regulation of vascular growth factors and their receptors occurs which 
contributes to tumor recurrence and progression 34. Direct up-regulation of 
VEGF after irradiation of various cancer cell lines has been reported 35. 
Radiation also induces transient tumor hypoxia which results in upregulation 
of hypoxia inducible factor -1 (HIF-1) which can stimulate VEGF and VEGF-
R2 expression. Therefore, simultaneous inhibition of both VEGFR and EGFR 
signaling through chronic administration of vandetanib in combination with 
cytotoxic therapy is expected to suppress the upsurge in pro-proliferative and 
angiogenic signaling resulting from CPT-11 and radiation-induced EGFR and 
VEGF. This suppression will thereby lead to inhibition of vascular protective 
mechanisms and growth factor mechanisms contributing to tumor regrowth.   
 
The increased tumor growth that was seen in this study following 
discontinuation of vandetanib suggests that inhibition of angiogenic and pro-
proliferative signaling is readily reversed. The current observations are in 
agreement with a number of both preclinical and clinical studies showing that 
tumors can adapt to anti-angiogenic treatment by undergoing “evasive 
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resistance” to angiogenesis inhibitors 36. Mechanisms of resistance include 
upregulation of alternative proangiogenic signaling pathways as well as 
recruitment of bone marrow-derived proangiogenic cells 37, 38. In addition, 
administration of vandetanib itself has been observed to increase VEGF 
production in certain cancer cell lines as well as in tumor xenografts 39, 40, 
thereby suggesting an additional contributing mechanism to tumor relapse. 
More studies will be needed to determine whether additional angiogenic 
pathways may be induced by triple modality treatment.  
 
Conclusions 
The results of this study provide a scientific rationale for testing the 
combination of vandetanib, CPT-11, and radiation in patients with CRC.  
Although the best schedule and sequencing for this triple modality treatment 
has yet to be determined, the tumor growth delay kinetics observed in this 
study suggest that improvement in colorectal tumor response can be obtained 
by concurrent and sustained post-sequencing of vandetanib with cytotoxic 
therapy, keeping in mind that prolonged chronic administration of the receptor 
tyrosine kinase inhibitors may lead to the development of resistance and the 
requirement for additional therapeutic agents as seen with other targeted 
agents, such as imatinib and gefitinib 41, 42. 
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Tables 
Table 1. Estimates of the average daily tumor growth rate and average tumor 
doubling time, by treatment group. 
Table 2. P-values for comparisons of treatment groups, on days 7, 14 and 21, 
after the start of treatment. 
Figures 
Figure 1.  Summary of treatment groups.  
LoVo cells were implanted s.c. into the right hind limbs of athymic NCR NUM 
male mice. Mice were randomized into eight experimental groups (11-16 
animals per group). Vandetanib was administered at 50 mg/kg daily p.o. for 
14 days, starting on day 1. CPT-11 was given at 15 mg/kg i.p. on days 1 and 
3. Radiation was given as three fractions (3 x 3 Gy) on days 1, 2, and 3. 
 
Figure 2.  Tumor growth curves in LoVo xenografts treated with 
vandetanib, CPT-11, and/or radiation. 
Individual mouse data for eight treatment groups (11-16 animals per group), 
along with fitted group curves. Vandetanib was administered at 50 mg/kg 
daily p.o. for 14 days, starting on day 1. CPT-11 was given at 15 mg/kg i.p. on 
days 1 and 3. Radiation was given as three fractions (3 x 3 Gy) on days 1, 2, 
and 3. 
 
Figure 3.  Estimated geometric mean tumor volume over time in LoVo 
xenografts treated with vandetanib, CPT-11, and/or radiation.  
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Vandetanib was administered at 50 mg/kg daily p.o. for 14 days, starting on 
day 1. CPT-11 was given at 15 mg/kg i.p. on days 1 and 3. Radiation was 
given as three fractions (3 x 3 Gy) on days 1, 2, and 3.  
 
Figure 4.  H&E stained sections of LoVo colorectal xenografts.  
All tumors were collected from animals on day 14 following start of treatment. 
Areas of necrosis are denoted by nec. Magnification 20 X. 
(A) Control (untreated) tumor, showing 2% necrosis. 
(B) Tumor from animal after administration of last dose of vandetanib, 
showing 15% necrosis.  
(C) Tumor from animal after administration of CPT-11 and RT, showing 20% 
necrosis. 
(D) Tumor from animal after administration of vandetanib and CPT-11, 
showing 10% necrosis. 
 
 
 
